Circulating adiponectin is inversely associated with risk of thyroid cancer: In vivo and in vitro studies

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 12, 2011, Pages

  Mitsiades, Nicholas ^a   Pazaitou Panayiotou, Kalliopi ^a,b   Aronis, Konstantinos N ^a   Moon, Hyun Seuk ^a   Chamberland, John P ^a   Liu, Xiaowen ^a   Diakopoulos, Kalliope N ^a   Kyttaris, Vasileios ^a   Panagiotou, Vasiliki ^b   Mylvaganam, Geetha ^a   Tseleni Balafouta, Sofia ^c   Mantzoros, Christos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; RECOMBINANT ADIPONECTIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RISK; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ADIPONECTIN; ADULT; FEMALE; HUMANS; MALE; RECEPTORS, ADIPONECTIN; RISK FACTORS; THYROID GLAND; THYROID NEOPLASMS;

EID: 83155168432     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2010-1908     Document Type: Article

References (25)

1. Calle EE, Kaaks R 2004 Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579-591 (Pubitemid 39025053)
2. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS 2007 Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 86:s858-s866
3. Mistry T, Digby JE, Desai KM, Randeva HS 2008 Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl-2 expression. BJU Int 101:1317-1322 (Pubitemid 351549632)
4. Ziemke F, Mantzoros CS 2010 Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 91:258S-261S
5. Kadowaki T, Yamauchi T 2005 Adiponectin and adiponectin receptors. Endocr Rev 26:439-451 (Pubitemid 40686653)
6. Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, Chrousos G, Trichopoulos D 2003 Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab 88:993-997 (Pubitemid 36337745)
7. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, Mantzoros CS 2007 Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev 16:308-313 (Pubitemid 46383351)
8. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS 2005 Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97:1688-1694 (Pubitemid 41672235)
9. Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS 2007 Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer 120:1573-1578 (Pubitemid 46355396)
10. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D 2004 Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89:1102-1107 (Pubitemid 38368397)
11. Körner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, Bullen J, Neuwirth A, Tseleni S, Mitsiades N, Kiess W, Mantzoros CS 2007 Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 92:1041-1048 (Pubitemid 46465681)
12. Bub JD, Miyazaki T, Iwamoto Y 2006 Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 340:1158-1166 (Pubitemid 43083400)
13. Nakayama S, Miyoshi Y, Ishihara H, Noguchi S 2008 Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis. Breast Cancer Res Treat 112:405-410
14. Ron E, Kleinerman RA, Boice Jr JD, LiVolsi VA, Flannery JT, Fraumeni Jr JF 1987 A population-based case-control study of thyroid cancer. J Natl Cancer Inst 79:1-12
15. Rezzónico JN, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H 2009 Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab Syndr Relat Disord 7:375-380
16. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H 2005 Plasma adiponectin and gastric cancer. Clin Cancer Res 11:466-472 (Pubitemid 40116868)
17. Dalamaga M, Karmaniolas K, Nikolaidou A, Chamberland J, Hsi A, Dionyssiou-Asteriou A, Mantzoros CS 2008 Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system. Eur J Cancer 44:1744-1753
18. Dalamaga M, Karmaniolas K, Panagiotou A, Hsi A, Chamberland J, Dimas C, Lekka A, Mantzoros CS 2009 Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. Cancer Causes Control 20:193-199
19. Dalamaga M, Nikolaidou A, Karmaniolas K, Hsi A, Chamberland J, Dionyssiou-Asteriou A, Mantzoros CS 2007 Circulating adiponectin and leptin in relation to myelodysplastic syndrome: a case-control study. Oncology 73:26-32 (Pubitemid 351465597)
20. Park JT, Yoo TH, Chang TI, Lee DH, Lee JH, Lee JE, Choi HY, Kang SW, Han DS, Ryu DR 2011 Insulin resistance and lower plasma adiponectin increase malignancy risk in nondiabetic continuous ambulatory peritoneal dialysis patients. Metabolism 60:121-126
21. Borena W, Stocks T, Jonsson H, Strohmaier S, Nagel G, Bjørge T, Manjer J, Hallmans G, Selmer R, Almquist M, Häggström C, Engeland A, Tretli S, Concin H, Strasak A, Stattin P, Ulmer H 2011 Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control 22:291-299
22. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R 2006 Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 345:271-279
23. Ahn KH, Lee SH, Park HT, Kim T, Hur JY, Kim YT, Kim SH 2010 Effect of adiponectin and sex steroid hormones on bone mineral density and bone formation markers in postmenopausal women with subclinical hyperthyroidism. J Obstet Gynaecol Res 36:370-376
24. Sieminska L, Niedziolka D, Pillich A, Kos-Kudla B, Marek B, Nowak M, Borgiel-Marek H 2008 Serum concentrations of adiponectin and resistin in hyperthyroid Graves' disease patients. J Endocrinol Invest 31:745-749
25. Lin SY, Huang SC, Sheu WH 2010 Circulating adiponectin concentrations were related to free thyroxine levels in thyroid cancer patients after thyroid hormone withdrawal. Metabolism 59:195-199